GAMMA Investing LLC Has $676,000 Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

GAMMA Investing LLC boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 36,430.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,151 shares of the company's stock after purchasing an additional 13,115 shares during the period. GAMMA Investing LLC's holdings in Tarsus Pharmaceuticals were worth $676,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TARS. Rhumbline Advisers raised its holdings in shares of Tarsus Pharmaceuticals by 2.1% during the fourth quarter. Rhumbline Advisers now owns 49,534 shares of the company's stock valued at $2,743,000 after acquiring an additional 1,019 shares during the period. Nations Financial Group Inc. IA ADV bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth approximately $332,000. Y Intercept Hong Kong Ltd bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth approximately $837,000. Bank of New York Mellon Corp grew its position in Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after acquiring an additional 498 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth $227,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock traded down $0.42 during mid-day trading on Friday, reaching $40.65. The company's stock had a trading volume of 1,281,705 shares, compared to its average volume of 700,683. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a market cap of $1.71 billion, a P/E ratio of -14.89 and a beta of 0.83. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. The firm's 50-day moving average is $45.09 and its two-hundred day moving average is $48.23.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on TARS. Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price target for the company. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $66.67.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 824,106 shares in the company, valued at $41,205,300. This trade represents a 0.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 8.97% of the stock is owned by insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.